{"id":"NCT01951170","sponsor":"Hoffmann-La Roche","briefTitle":"An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis","officialTitle":"An Open-Label Study to Evaluate Non-Progression Of Structural Joint Damage Of Subcutaneous Tocilizumab In Patients With Moderate To Severe Active Rheumatoid Arthritis (Ac-Cute)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2015-08","completion":"2015-08","firstPosted":"2013-09-26","resultsPosted":"2016-09-21","lastUpdate":"2016-09-21"},"enrollment":52,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab","otherNames":["RoActemra®/Actemra®"]}],"arms":[{"label":"Tocilizumab","type":"EXPERIMENTAL"}],"summary":"This open-label, single-arm study will evaluate the efficacy and safety of tocilizumab in patients with active moderate to severe rheumatoid arthritis. Participants will receive a subcutaneous dose of tocilizumab 162 mg once weekly. The anticipated time on study treatment is 24 weeks.","primaryOutcome":{"measure":"Change From Baseline in Genant-modified Total Sharp Score (mTSS)","timeFrame":"From baseline to Week 24","effectByArm":[{"arm":"Tocilizumab","deltaMin":7,"sd":null}],"pValues":[{"comp":"OG000","p":"0.83"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":15},"locations":{"siteCount":10,"countries":["Australia"]},"refs":{"pmids":["30649524","29849651","29244149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":52},"commonTop":["Upper respiratory tract infection","Rheumatoid arthritis","Neutropenia","Diarrhoea","Mouth ulceration"]}}